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Endocannabinoids in 
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Proper cholesterol transport is crucial for the functionality of cells. In C. elegans, certain cholesterol 
derivatives called dafachronic acids (DAs) govern the entry into diapause. In their absence, worms 
form a developmentally arrested dauer larva. Thus, cholesterol transport to appropriate places 
for DA biosynthesis warrants the reproductive growth. Recently, we discovered a novel class of 
glycosphingolipids, PEGCs, required for cholesterol mobilization/transport from internal storage 
pools. Here, we identify other components involved in this process. We found that strains lacking 
polyunsaturated fatty acids (PUFAs) undergo increased dauer arrest when grown without cholesterol. 
This correlates with the depletion of the PUFA-derived endocannabinoids 2-arachidonoyl glycerol and 
anandamide. Feeding of these endocannabinoids inhibits dauer formation caused by PUFAs deficiency 
or impaired cholesterol trafficking (e.g. in Niemann-Pick C1 or DAF-7/TGF-β mutants). Moreover, in 
parallel to PEGCs, endocannabinoids abolish the arrest induced by cholesterol depletion. These findings 
reveal an unsuspected function of endocannabinoids in cholesterol trafficking regulation.
Cholesterol is a lipid used by virtually all eukaryotic organisms. Its primary role as a structural component of cell 
membranes is to regulate their fluidity, permeability and topology. However, cholesterol also serves as a precursor 
of a plethora of other important biomolecules, such as steroid hormones, oxysterols and bile acids. Thus, tight 
regulation of the intake, biosynthesis, transport and metabolism of cholesterol is crucial for cellular integrity and 
functionality. In cells, cholesterol needs to be delivered to various destinations where it performs its structural 
functions or is further metabolized. This process is known as intracellular cholesterol trafficking and its impor-
tance is underscored by an amounting number of pathologies resulting from its impairment, including athero-
sclerosis and many genetic disorders such as the Niemann-Pick type C (NPC) disease and the Tangier disease1,2. 
Therefore, the cholesterol trafficking machinery has been intensively studied and many protein mediators of 
vesicular and non-vesicular cholesterol transport have been described2.
C. elegans is an excellent model for studying cholesterol trafficking and metabolism because worms are unable 
to synthesize cholesterol and require its presence in the diet. This allows an easy manipulation of worm sterol 
composition by introducing variations of its levels in the diet3. Following cholesterol intake, the systemic dis-
tribution of this lipid in worms is mediated by various transport systems, including the vitellogenin lipopro-
tein particles4. After receptor-mediated endocytosis of cholesterol carriers, cholesterol is trafficked through the 
endolysosomal system and directed to other cellular compartments with the assistance of the Niemann-Pick 
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type C1 (NPC1) homologs NCR-1 and NCR-25. The importance of this process is demonstrated by the fact that 
ncr-2;ncr-1 null mutants fail to produce fertile adults and instead arrest at the dauer diapause, an alternative devel-
opmental stage for survival under harsh conditions such as overcrowding and starvation5. This developmental 
arrest has been shown to occur as a result of a decreased production of bile acid like steroid hormones called 
dafachronic acids (DAs)5,6. These important hormones integrate cues from various signaling pathways, including 
the transforming growth factor (TGF)-β-like (defined by the TGF-β homologue DAF-7) pathway, the insulin-like 
pathway (involving nematode insulin receptor DAF-2) and the cyclic GMP pathway, by binding a nuclear hor-
mone receptor (NHR) named DAF-126–10. In its DA-bound form, DAF-12 stimulates reproductive development, 
whereas in the absence of DAs it promotes dauer arrest.
Even though cholesterol is associated with cell membranes and interacts with multiple lipid species, very 
little is known about how lipids influence cholesterol trafficking. One of the few known examples is the positive 
effect of the phospholipid lysobisphosphatidic acid on the trafficking of cholesterol through the endolysosomal 
compartment11. Owing to the huge diversity of membrane lipids, multiple other lipid species might emerge as 
additional modulators of the cholesterol trafficking process. More recently, we have discovered a novel class of 
glycolipids, phosphoethanolamine glucosylceramides (PEGCs), that stimulates the trafficking of cholesterol in C. 
elegans10. PEGCs stimulate the growth of worms under conditions of cholesterol scarcity and abolish the devel-
opmental arrest of ncr-2;ncr-1 mutants. By enhancing the mobilization of cholesterol from intracellular pools, 
PEGCs stimulate the production of DAs, thus inhibiting the dauer promoting activity of DAF-12.
Another class of lipids, endocannabinoids, have been implicated in the regulation of dauer formation as well12. 
These molecules are conserved lipid mediators that regulate multiple biological processes in a variety of organ-
isms13,14. Previous studies have shown that one class of endocannabinoids, N-acylethanolamines (NAEs), antago-
nize dauer formation in C. elegans. NAEs are endocannabinoids composed of a fatty acyl chain of varying length 
and unsaturation (polyunsaturated fatty acids, PUFAs) linked to an ethanolamine head group. It has been shown 
that supplementation with the NAE eicosapentanoyl ethanolamide (EPEA), was able to rescue the dauer pheno-
types of daf-2 mutant lines12.
In this study, we show that the synthesis of PUFAs is important for cholesterol trafficking and, accordingly, for 
the reproductive development of worms. Further characterization of the bioactive PUFA-derivatives revealed that 
arachidonoyl-ethanolamine (AEA) and 2-O-arachidonoyl-glycerol (2-AG), the best-characterized arachidonic 
acid containing endocannabinoids15, are responsible for abolishing dauer larva arrest by stimulating cholesterol 
trafficking. We also show that endocannabinoids via mobilization of internal cholesterol pools can rescue the 
dauer arrest induced by PEGCs deficiency/cholesterol depletion. We propose that endocannabinoids and PEGCs 
act synergistically to promote growth and development by regulating cholesterol homeostasis in C. elegans.
Results
Depletion of PUFAs leads to enhanced dauer formation. In a previous study, we have shown that 
C. elegans interrupts reproductive development and arrests as a dauer-like larva (L2*) with incomplete molt-
ing when grown for two generations without cholesterol3. More recently, we have found that this arrest can be 
abolished by supplementation of PEGCs, substances belonging to a novel class of lipids that mobilizes internal 
pools of cholesterol10. We were interested to further investigate this process and to identify other components 
that might be involved in it. We reasoned that strains aberrant in cholesterol mobilization would arrest already 
in the first generation without externally provided sterols. Indeed, a small screening performed on a mutant 
strain collection (Mende, F. and Kurzchalia, T.V., unpublished data) indicated that one of them, with inactive Δ6-
desaturase [fat-3(ok1126)] showed growth defects already in the first, rather than in the second generation when 
grown without cholesterol. Unlike the wild type strain, that produced almost 100% gravid adults in the first gener-
ation without cholesterol, fat-3 displayed a high incidence of arrested larvae (Fig. 1a) with typical dauer morphol-
ogy (Supplementary Figure 1). This mutant strain bears a large deletion in the coding region of gene fat-3, and is 
null for FAT-3 desaturase. Animals accumulate linoleic and α-linolenic acids and are unable to produce the major 
C20 PUFAs found in C. elegans: arachidonic (20:4 (n-6), AA) and eicosapentanoic acid (20:5(n-3), EPA)16,17.
Next, we set out to confirm the interaction between the PUFA biosynthesis pathways and the dauer forma-
tion regulating pathways. In particular, we tested the interaction with the DAF-7/TGF-β pathway that regulates 
dauer development by affecting sterol trafficking and metabolism10,18,19. In our previous study we have shown that 
temperature-sensitive daf-7 mutants with “dauer formation constitutive” (Daf-c) phenotype are hypersensitive to 
cholesterol depletion and form dauer larvae in the absence of external cholesterol already at the semi-permissive 
growth temperature despite internally stored sterols10. We reasoned that if the biosynthesis of PUFAs is connected 
with this regulatory pathway, depletion of PUFAs should enhance the phenotype of daf-7. To this end, we gener-
ated a double mutant strain for fat-3(ok1126) and daf-7(e1372) and scored dauer formation. When grown at the 
semi-permissive growth temperature (20° C), daf-7(e1372);fat-3(ok1126) double mutants formed significantly 
more dauers (~85%) than the parental daf-7 strain (<10%) (Fig. 1b,c). Moreover, enhanced dauer formation 
in double mutants was fully abolished when the medium was supplemented with DA (Fig. 1b). These results 
suggest that a decrease in the synthesis of C20 PUFAs could be leading to deficiency of DAs. We speculated that 
depletion of PUFAs might exacerbate cholesterol deficiency due to a decrease in its delivery rate from storage sites 
to the locations of DA production. Therefore, we tested whether very high cholesterol availability in the growth 
medium was sufficient to compensate for the loss of FAT-3 in daf-7;fat-3 animals. As shown in Fig. 1d, providing 
a high-cholesterol diet did promote dauer recovery of daf-7;fat-3 mutants.
Arachidonic acid-containing endocannabinoids abolish dauer formation of daf-7;fat-3 and daf-
7;fat-4 mutants. Then, we asked which PUFA-derived molecules could be responsible for the dauer arrest of 
daf-7;fat-3 double mutants. PUFAs are metabolized into many potent bioactive compounds such as eicosanoids 
and endocannabinoids20. The latter, shown in Fig. 2a, might be one of the most likely class of candidates because 
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previous studies have shown that N-acylethanolamines (NAEs) antagonize dauer formation in C. elegans12. 
Using high-performance liquid chromatography coupled to mass spectrometry (HPLC MS/MS), we found that, 
in agreement with a previous report21, N2 has detectable amounts of 2O-arachidonoylglycerol (2-AG, Fig. 2a) 
and arachidonoyl-ethalonamine (anandamide or AEA, Fig. 2a) (Fig. 2b and Supplementary Table 1). We also 
determined that these arachidonic acid-containing endocannabinoids are synthesized by daf-7 (Fig. 2b). In con-
trast, both fat-3 and daf-7;fat-3 strains do not synthesize PUFA-derived endocannabinoids to detectable levels 
(Fig. 2b). Next, we tested the capability of the detected endocannabinoid molecules to suppress dauer formation 
of daf-7;fat-3. We found that supplementation of the media with 2-AG and AEA significantly reduced the Daf-c 
phenotype of daf-7;fat-3 worms (Fig. 2c). In contrast, EPEA failed to rescue the Daf-c phenotype of daf-7;fat-3 
(Fig. 2a,c).Treatment with AA, which is both a precursor as well as the hydrolytic breakdown product of both 
2-AG and AEA15, was unable to promote reproductive growth of daf-7;fat-3 (Fig. 2c). However, in a previous 
study, we have established the use of fatty acid methyl esters (FAMEs) instead of the corresponding free fatty acids 
due to the much higher rescue activities of the former22. FAMEs are more active presumably because membranes 
Figure 1. PUFA-deficient mutants fat-3 and daf-7;fat-3 exhibit a dauer-like or a Daf-c phenotype, respectively. 
(a) Unlike wild-type worms, fat-3(ok1126) mutants are incapable of synthesizing PUFAs and undergo a dauer-
like arrest in the first generation when grown in cholesterol-free media. One-way analysis of variance p < 0.001. 
All pairwise multiple comparison procedures (Holm-Sidak method), (*) indicates statistically significant 
difference with fat-3/solvent, p < 0.001. Bars represent mean values and error bars represent standard errors. 
The number of independent experiments is n = 3 for all conditions. (b) While daf-7 worms form ~10% dauers at 
20 ºC, fat-3 worms do not form dauers. In stark contrast, double mutant daf-7;fat-3 forms ~85% dauers at 20 ºC, 
and addition of DA suppresses dauer formation almost completely. One-way analysis of variance p < 0.001. All 
pairwise multiple comparison procedures (Holm-Sidak method): (*) indicates statistically significant difference 
with daf-7, p < 0.001. Bars represent mean values and error bars represent standard errors. The number of 
independent experiments is n = 5 for daf-7, and n = 13 for fat-3 and daf-7; fat-3. [DA] = 90 nM. (c) Introducing 
the fat-3 null-mutation into background daf-7 increases dauer formation significantly (dauers are indicated 
with arrowheads). Representative images are taken from at least three experiments. Scale bars, 0.5 mm. (d) daf-
7;fat-3 dauers can partly bypass dauer arrest if grown in excess cholesterol (130 µM). (*) indicates statistically 
significant difference to control plates (13 µM cholesterol). t-test, p < 0.001. Bars represent mean values and 
error bars represent standard errors. The number of independent experiments is n = 14 for daf-7;fat-3 at 13 µM 
cholesterol, and n = 2 for daf-7;fat-3 at 130 µM cholesterol.
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are more permeable for them. Indeed, addition of AA-methyl ester (methyl-AA) to daf-7;fat-3 worms signifi-
cantly reduced the Daf-c phenotype (Fig. 2c). This raised the question whether methyl-AA is a precursor of 2-AG 
and/or AEA23 or AA has an effect by itself. In order to find out whether methyl-AA serves as a precursor of 2-AG 
and AEA, lipid extracts of fat-3 and daf-7;fat-3 mutants fed with methyl-AA were analyzed by LC-MS/MS. This 
analysis revealed that indeed these mutants were capable to synthesize both 2-AG and AEA (Supplementary 
Table 1) upon methyl-AA supplementation. Importantly, we found that noladin24 (Fig. 2a), a non-hydrolysable 
analog of 2-AG, was also able to rescue the Daf-c phenotype of daf-7;fat-3 to an extent comparable to the effect 
of 2-AG, demonstrating that the endocannabinoids are not merely precursors for other AA-derived compounds 
(Fig. 2c).
Although AA-derived endocannabinoids rescue the dauer phenotype of daf-7;fat-3, it could be argued that 
this double mutant is unable to synthesize dihommo-γ-linolenic acid [20:3(n-6)] (DGLA) and eicosatetraenoic 
acid [20:4(n-3)], [ETA (n-3)] and that endocannabinoids derived from these C20 PUFAs could serve the same 
function as 2-AG or AEA. To answer this question we generated daf-7;fat-4 double mutant strain that synthesizes 
DGLA and ETA (n-3), but is unable to synthesize AA25 due to its deficiency in Δ5 fatty acid desaturase enzyme 
FAT-4. daf-7;fat-4 double mutant displays a very strong Daf-c phenotype similar to the one observed in daf-7;fat-3 
(Supplementary Figure 2a). Furthermore, supplementation of the growth medium with an excess of cholesterol, 
DA, 2-AG and noladin ether substantially lowers dauer formation in daf-7;fat-4 (Supplementary Figures 2a and 
2b). These results demonstrate the specificity of AA-derived endocannabinoids to rescue the enhanced dauer 
Figure 2. Endocannabinoids rescue the Daf-c phenotype of daf-7;fat-3 worms. (a) Chemical structures of the 
endocannabinoid molecules assayed. (b) Extracted ion chromatograms of HPLC- MS/MS experiments in order 
to detect the endocannabinoids 2-AG and AEA in lipid extracts of the following worm strains: N2, daf-7, fat-3 
and daf-7;fat-3. The upper panels show the chromatograms of the analytical standards 2-AG and AEA. (c) daf-
7;fat-3 dauers cannot be rescued by supplementation with EPEA. However, addition of the endocannabinoids 
2-AG and AEA, and the non-hydrolysable noladin ether suppresses dauer formation significantly. 
Supplementation of methyl-AA also prevents daf-7;fat-3 dauer formation. Kruskal-Wallis one-way analysis 
of variance on ranks, p < 0.001. Multiple comparisons versus control group (Dunn’s Method). (*) indicates 
statistically significant difference with solvent, p < 0.05. Bars represent mean values and error bars represent 
standard errors. The number of independent experiments is n = 14 for solvent, n = 2 for EPEA and noladin, 
n = 14 for 2-AG, n = 4 for AEA and AA, and n = 8 for methyl-AA. The concentration of all additives is 50 µM.
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formation of daf-7 animals deprived of C20 PUFAs. Taken together, we conclude that endocannabinods contain-
ing AA residues are the active compounds promoting reproductive development.
Endocannabinoids do not substitute for DA. As shown above, both endocannabinoids and DAs are 
able to rescue the dauer constitutive phenotype displayed by daf-7;fat-3 (Figs 1b and 2c). This raised the possibil-
ity that the endocannabinoid compounds were merely substituting for DAs as DAF-12 ligands. To address this 
question, we tested whether 2-AG and AEA were able to compensate for the deficiency of DAF-9 cytochrome 
P450 enzyme, necessary for the production of DA from cholesterol6,26. As seen in Supplementary Figure 3, unlike 
DA, 2-AG and AEA failed to inhibit dauer formation in daf-9(dh6) mutants. This indicates that these endocan-
nabinoids cannot substitute for DA. Thus, it seems likely that these endocannabinoids inhibit dauer formation by 
enhancing the synthesis of DAs.
Endocannabinoids rescue the arrest induced by cholesterol depletion through its mobiliza-
tion. Our previous studies have demonstrated that PEGCs also enhance the synthesis of DAs by mobilization 
of internal pools of maternally deployed cholesterol10. Because of this activity, PEGCs are also able to abolish the 
developmental arrest caused by cholesterol starvation in the second generation of worms grown on sterol-depleted 
medium10. We asked whether endocannabinoids could similarly inhibit the arrest of cholesterol-depleted worms. 
Indeed, addition of 2-AG to sterol-lacking medium resulted in formation of many late stage (L4) larvae and adults 
in the N2 wild-type strain in the second generation, whereas the untreated worms arrested mainly as L2* larvae 
as published before (Fig. 3a)3.
We next set out to investigate whether AEA and 2-AG have the ability to mobilize internal reserves of sterols 
in C. elegans. First, we made use of daf-7 mutants which are hypersensitive to cholesterol starvation. They form 
dauers already in the first generation even at permissive temperature (15˚C) when the external cholesterol source 
is missing. Although these worms receive high amounts of maternal cholesterol, they are unable to use this sterol 
for DA synthesis presumably due to an impairment in mobilizing sterols efficiently10. We found that upon cho-
lesterol deprivation, 2-AG rescues the dauer arrest of daf-7 animals grown without cholesterol (Fig. 3b). Next, we 
investigated the interaction of endocannabinoids with the NPC1 sterol-trafficking system27. As mentioned earlier, 
cholesterol transport in C. elegans is partly mediated by the NPC1 homologs NCR-1 and NCR-228. Because of this, 
double mutant ncr-2(nr2023);ncr-1(nr2022) displays constitutive dauer formation5. This dauer formation can be 
rescued by supplementation with DAs5,7. As seen in Fig. 3c, 2-AG could also largely suppress ncr-2;ncr-1 dauer 
formation. Moreover, the Daf-c phenotype of ncr-2;ncr-1, as well as of daf-7, was diminished by RNAi against 
faah-1, a gene encoding a conserved fatty acid amide hydrolase (FAAH) enzyme, responsible for the breakdown 
of N-acylethanolamines such as AEA and EPEA in worms12 (Fig. 3d and Supplementary Figure 4).
The ability of the AA-derived endocannabinoids to rescue the development of cholesterol-depleted worms 
pointed out to the possibility that the endogenous production of these compounds might be enhanced in 
response to cholesterol withdrawal. This could be a mechanism to optimize cholesterol mobilization when the 
diet is not rich in sterols. In agreement with this hypothesis, we found that removing cholesterol from the growth 
medium resulted in a reproducible two-fold increase in 2-AG levels in N2 animals already in the first generation 
(Supplementary Table 2). Taken together, our data suggest that in C. elegans endocannabinoids exert their effects 
on post-embryonic development by enhancing the efficiency of cholesterol trafficking and the utilization of inter-
nal pools.
Endocannabinoids and PEGCs are acting through parallel pathways. Next, we examined how 
2-AG and AEA are connected to recently discovered PEGCs: Can endocannabinoids rescue PEGCs deficiency? 
And vice versa, can PEGCs rescue endocannabinoid deficiency?
To induce PEGCs deficiency, we inhibited the synthesis of their precursors, the glucosylceramides 
(GlcCer). For this, two approaches have been used. Firstly, we decided to decrease C15iso and C17iso mon-
omethyl branched-chain fatty acids (mmBCFA), needed for the synthesis of the long-chain base in C. elegans29 
(Supplementary Figures 5 and 6). For this, we applied RNAi of LET-767, the major 3-ketoacyl-CoA reductase, 
necessary for the elongation of long-chain and branched-chain fatty acids. RNAi of LET-767 in wild type worms 
leads to multiple developmental phenotypes in the first generation and early larval arrest in the second generation 
(L1-L2)22. Indeed, RNAi against LET-767 in daf-7 mutants grown at 20 °C significantly increases the Daf-c pheno-
type of the strain (Fig. 4a). GC-MS analysis of the relative fatty acid profiles of control and let-767 RNAi animals 
confirmed that RNAi treatment leads to a strong decrease in the levels of C15iso and C17iso mmBCFAs, but 
not of PUFAs (Supplementary Table 3). Accordingly, as seen in Fig. 4b, supplementation with C17iso mmBCFA 
methyl esters rescued the let-767 RNAi-induced dauer arrest of daf-7 worms. Astoundingly, both 2-AG and AEA 
also rescued the dauer formation observed in daf-7 animals subjected to let-767 RNAi (Fig. 4b). To exclude the 
possibility that endocannabinoids act by elevating levels of mmBCFAs, i.e. by inducing (a) not yet identified alter-
native 3-ketoacyl-CoA reductase(s), we performed GC-MS analysis of mmBCFA in daf-7 let-767 RNAi worms in 
the presence of 2-AG (Supplementary Table 4). This experiment clearly shows that endocannabinoid treatment 
does not increase mmBCFA. In consistency with impaired cholesterol trafficking in daf-7 let-767 (RNAi), dauer 
formation was partly inhibited by high cholesterol levels in the medium (Fig. 4c).
The second approach to deplete PEGCs was to treat daf-7 with PDMP, an inhibitor of the final glucosylation 
step in the synthesis of GlcCer (Supplementary Figure 6). We found that DA, high cholesterol and endocannabi-
noids rescue daf-7 dauers generated in the presence of PDMP (Fig. 4d)10. However, as expected, PDMP treatment 
could not be rescued by addition of mmBCFA C17iso methyl ester because PDMP inhibits a later step of the 
synthesis of PEGCs. Thus, PEGCs deficiency could be rescued by supplementation with endocannabinoids.
In another set of experiments, we investigated whether PEGCs could abolish dauer formation in the endo-
cannabinoids deficient strain daf-7;fat-3. As seen in Fig. 4e, synthetic mmPEGC-C22, the major PEGC species 
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found in worms10, can partially rescue the dauer formation induced by the absence of endocannabinoids. Taking 
altogether, we propose that two unrelated lipid species, endocannabinoids and PEGCs, regulate worm cholesterol 
transport/mobilization through parallel pathways.
Discussion
The major finding of our study is that the endocannabinoids 2-AG and AEA regulate the transport/mobilization 
of cholesterol in C. elegans, which results in enhanced DA production. Several lines of evidence support this 
notion: endocannabinoids (i) abolish the developmental arrest caused by cholesterol depletion in wild-type and 
daf-7 worms, (ii) stimulate the reproductive development of daf-7 worms with diminished glucosylceramide/
PEGC synthesis and (iii) rescue ncr-2;ncr-1 mutants with aberrant cholesterol transport.
Figure 3. Endocannabinoids suppress dauer formation induced by cholesterol depletion. (a) Wild-type control 
animals grown for two generations in the absence of cholesterol arrest as L2-like larvae (upper micrograph), 
however, when fed with 2-AG worms form adults (lower micrograph). Representative images from at least 
three experiments. Scale bars, 0.25 mm. (b) When grown in the absence of cholesterol daf-7 worms form ~65% 
dauers in the first generation at 15 ºC. This arrest is largely suppressed by the addition of either cholesterol, or 
DA, or by the endocannabinoid 2-AG. (*) indicates statistically significant difference with solvent control. t-test, 
p = 0.002. Bars represent mean values and error bars represent standard errors. The number of independent 
experiments is n = 5 for solvent, and 2-AG, n = 7 for cholesterol, and n = 4 for ∆7-DA. [Cholesterol] = 13 µM. 
[DA] = 90 nM. [2-AG] = 50 µM. (c) 2-AG suppresses the Daf-c phenotype of ncr-2;ncr-1 at 25 ºC. (*) indicates 
statistically significant difference with solvent control. Kruskal-Wallis one-way analysis of variance on ranks, 
p < 0.001 and all pairwise multiple comparison procedures (Student-Newman-Keuls Method), p < 0.05. Bars 
represent mean values and error bars represent standard errors. The number of independent experiments is 
n = 6 for all conditions. [Cholesterol] = 13 µM. [DA] = 90 nM. [2-AG] = 50 µM. (d) faah-1 RNAi reduces the 
percent of dauer formation of strain ncr-2;ncr-1 at 25 ºC. (*) indicates statistically significant difference with 
solvent empty vector control (EV). One Way Analysis of Variance (p < 0.001) and comparison by Holm-Sidak 
method, p < 0.001 in both cases. Bars represent mean values and error bars represent standard errors. The 
number of independent experiments is n = 6 for all conditions tested. [DA] = 90 nM.
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Figure 4. PEGCs and endocannabinoids stimulate cholesterol transport by employing parallel pathways. (a) 
RNAi of let-767 leads to a significant increase of dauers compared to control plates in daf-7 mutant background 
(empty vector; from ~20% to ~80%), but has no effect on wild type (N2) dauer formation. Kruskal-Wallis one-
way analysis of variance on ranks, p < 0.001, All pairwise multiple comparison procedures (Dunn’s Method), 
(*) indicates statistically significant difference between daf-7/empty vector and daf-7/let-767 RNAi, p < 0.05. 
Bars represent mean values and error bars represent standard errors. The number of independent experiments 
is n = 6 for N2/empty vector, and N2/let-767 RNAi, n = 27 for daf-7/empty vector, n = 33 for daf-7/let-767 
RNAi, and n = 6 for daf-7/let-767 RNAi+DA. [DA] = 90 nM. (b) daf-7 on let-767 RNAi at 20 ºC forms ~80% 
dauers. Supplementation with either of the endocannabinoids 2-AG and AEA, or the addition of methyl-C17iso 
suppresses dauer formation significantly. Kruskal-Wallis one-way analysis of variance on ranks, p < 0.001. 
Multiple comparisons versus control group (Dunn’s Method). (*) indicates statistically significant difference 
with empty vector, p < 0.05. Bars represent mean values from at least three independent experiments and error 
bars represent standard errors. [2-AG] or [AEA] = 50 µM. [methyl-C17iso] = 100 µM. (c) daf-7 let-767 RNAi 
worms partly bypass dauer arrest if grown in excess cholesterol (130 µM). (*) indicates statistically significant 
difference with control plates (13 µM cholesterol). Mann-Whitney rank sum test p = 0.013. Bars represent 
mean values and error bars represent standard errors. The number of independent experiments is n=26 for 
daf-7 let-767 RNAi at 13 µM cholesterol, and n = 4 for daf-7 let-767 RNAi at 130 µM cholesterol. (d) Inhibition 
of the d17iso-glucosylceramide synthesis (and hence PEGCs) by PDMP treatment leads to an increase in 
dauer formation in daf-7 background, that can be largely suppressed by endocannabinoids, DA and excess 
cholesterol, but not by methyl-C17iso. One-way analysis of variance, p < 0.001. Multiple comparisons versus 
control group (Holm-Sidak method). (*) indicates statistically significant difference with PDMP treatment, 
p < 0.001 for all conditions except for empty vector (p = 0.002). Bars represent mean values and error bars 
represent standard errors. The number of independent experiments is n = 3 for all conditions. [DA] = 90 nM. 
[Cholesterol] = 130 µM. [2-AG] or [AEA] = 50 µM. [methyl-C17iso] = 100 µM. (e) mmPEGC-C22 is partly 
able to suppress dauer formation of daf-7;fat-3 at 20 ºC. One-way analysis of variance, p < 0.001. Multiple 
comparisons versus control group (Holm-Sidak method). (*) indicates statistically significant difference with 
solvent control, p < 0.001 for both conditions. Bars represent mean values and error bars represent standard 
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Based on our data, we propose a tentative scheme of the interaction between endocannabinoids and PEGC 
in the control of cholesterol transport (Fig. 4f). Multiple reactions produce the precursors diacylglycerol (DAG), 
N-acyl-phosphatidylethanolamine (NAPE), and GlcCer required for the synthesis of 2-AG, AEA and PEGCs, 
respectively. The conversions of these precursors to the active compounds are carried out by not yet identified 
enzymes in C. elegans. 2-AG and AEA are probably produced by enzymes homologous to the mammalian DAG 
lipase (DAGL) and NAPE-specific phospholipase D (NAPE-PLD)30, although alternative biosynthetic pathways 
also exist12,20,31. The enzymatic system required for PEGCs production is completely unknown. Intriguingly, 
PEGCs cannot be synthesized in the absence of functional NCR-1 and NCR-2 proteins10. This suggests that in 
worms PEGCs mediate cholesterol transport downstream of NPC1. Endocannabinoids and PEGCs act in parallel 
to stimulate the mobilization/transport of cholesterol. This leads to delivery of the latter to DAF-9, production of 
DA and inhibition of the dauer-promoting activity of DAF-12. It should be noted that, in addition to their effect 
as regulators of cholesterol mobilization, endocannabinoids might also stimulate the synthesis of DA via regu-
lation of alternative signaling pathways such as the monoaminergic neurotransmission, GPCR and MAP kinase 
– mediated cascades, etc.32,33. PEGCs, on the other hand, could also display pleiotropic effects due to their specific 
glycospingolipid structure: they might physically interact with cholesterol or affect its distribution by regulating 
different properties of the cellular membranes: their topology, fluidity or permeability34.
One important implication of the fact that the endocannabinoids and GlcCer/PEGCs act in parallel is that 
endocannabinoids might be involved in the regulation of a plethora of other known glucosylceramide-dependent 
processes in worms. These include the activation of the nutrient-sensing TOR signaling, the establishment of 
epithelial polarity in intestinal cells, foraging behavior and sensory neuron maturation29,35–37. Future studies will 
reveal the relationships between glycosphingolipids, cholesterol and endocannabinoids in the control of these 
processes.
Many of the physiological effects produced by endocannabinoids are not completely understood. Some of 
them may reflect their influence on cholesterol trafficking. In higher organisms, many aspects of the intracellular 
cholesterol transport are regulated by the transcription factors LXR and SREBP1. Intriguingly, LXR is one of the 
vertebrate homologs of DAF-12, which binds oxysterols38. This points to the interesting possibility that LXR 
and DAF-12 might have similar endocannabinoid-dependent activities in regard to the control of cholesterol 
homeostasis. On the other hand, endocannabinoids and endocannabinoid agonists are known to increase the 
hepatic expression of SREBP in mice39. Whether 2-AG and AEA could also operate via SREBP in worms is worth 
investigating.
Finally, deregulation of cholesterol and lipid homeostasis has major consequences on development and dis-
ease. Cholesterol metabolism in particular is closely interrelated with cardiovascular disease in humans. It is well 
known that dietary supplementation with omega-6 polyunsaturated fatty acids (PUFAs) reduces the risk of car-
diovascular disease. In part, this is attributable to the observation that increased plasma levels of omega-6 PUFAs 
favorably affect plasma LDL-cholesterol and HDL-cholesterol levels40,41. While it is widely accepted that lipid 
metabolism is linked to cholesterol homeostasis38,42, exactly how PUFAs control cholesterol balance and metabo-
lism remains largely unexplored. Hence, our findings point up the exciting scenario that the role of PUFA-derived 
endocannabinoids could be conserved in humans. Thus, unraveling the mechanisms by which endocannabinoids 
affect sterol-regulated processes in C. elegans could have important implications for the better understanding 
of human pathological conditions associated with impaired cholesterol homeostasis, such as atherosclerosis, 
non-alcoholic fatty liver disease and Niemann-Pick type C disease.
Materials and Methods
Materials. 2-AG, AEA, noladin, EPEA and DL-threo-PDMP were purchased from Cayman Chemical (Ann 
Arbor, Michigan, USA). Cholesterol, AA, C17iso fatty acid, Dubelcco´s medium (DMEM) and antioxidant BHT 
were purchased from Sigma (Sigma-Aldrich, St. Louis, Missouri, USA). mmPEGC-C2210, Δ4-DA and Δ7-DA 
were provided by Prof. H.-J. Knölker43–45.
The worm strain N2 Bristol and the single mutants daf-7(1372), fat-3(ok1126), fat-4 (ok958), ncr-1;ncr-2 
(JT10800) were obtained from Caenorhabditis Genetics Center (CGC). daf-9(dh6);dhEx24 was provided by Prof. 
A. Antebi.
Growth and maintenance of worm strains. Worms were routinely propagated on nematode growth 
medium (NGM) agar plates seeded with E. coli OP5046. Saturated cultures of E. coli OP50 or NA22 grown in 
lysogeny broth (LB) medium were concentrated 10 times and spread on NGM-agar plates. Worms were 
placed on the plates either as mixed stage populations or as embryos obtained by hypochlorite treatment. The 
temperature-sensitive Daf-c mutants were grown at 15 °C to grow in the reproductive mode and at 25 °C to arrest 
as dauer larvae.
errors. The number of independent experiments is n = 2 for all conditions. [DA] = 1 µM. [mmPEGC-C22] = 0.5 
mM. (f) Endocannabinoids and PEGCs act in parallel to promote transport/mobilization of cholesterol from 
internal pools. Endocannabinoids are synthesized from their precursors DAG and NAPE most probably by 
DAGL and NAPE-PLD enzymatic activities. The enzyme(s) that produce(s) PEGC from d17iso-GlcCer is(are) 
unknown but the synthesis is dependent on NCR-1/2. Both endocannabinoids and PEGCs have the ability to 
mobilize cholesterol. The latter is then delivered to the sites of DAF-9 mediated DA synthesis. After systemic 
distribution of DA within the organism, it binds and inhibits the dauer-promoting activities of DAF-12. DAG 
– diacylglycerol; NAPE - N-acyl-phosphatidylethanolamine; DAGL - DAG lipase; NAPE-PLD - NAPE-specific 
phospholipase D.
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RNAi by feeding. RNAi against let-767 was performed with E. coli HT115 double-stranded RNA (dsR-
NA)-producing strain from the Ahringer library. RNAi was performed in the first generation. Bleached embryos 
were left to hatch overnight in M9 at 20 °C and the resulting L1s were seeded to RNAi plates and grown at 20 °C 
or 15 °C according to the experiment. Similarly, faah-1 RNAi was performed in the first generation. Unlike the 
experiments with let-767, the worms subjected to faah-1 RNAi were seeded on the dsRNA-producing E. coli as 
embryos. Finally, the dauer phenotype was scored after 72 h or 144 h, depending on the assay. For biochemical 
analysis worms were harvested from RNAi plates after 72 h.
Dauer formation assays. In general, 80–100 L1s or embryos were transferred to NGM plates seeded with 
E. coli (HT115) containing RNAi against let-767, faah-1 or empty vector as a negative control. The supplementa-
tion with endocannabinoids (final concentration 50 µM), arachidonic acid (final concentration 50 µM), methyl 
esters from different fatty acids (final concentration 50 µM), mm-PEGC-C22 (final concentration 10 µM) and 
DL-threo-PDMP (final concentration 20 µM) was added to the bacteria immediately prior to seeding. The final 
concentrations of these compounds were calculated according to the volume of the NGM agar used for the prepa-
ration of the plates. It should be noted that the active concentrations of mm-PEGC-C22 published before10 have 
been calculated according to the volume of the bacterial loan seeded on the agar/agarose surface. If calculated 
using the latter method, the concentration of mm-PEGC-C22 used here would be 500 µM. Finally, after 72 h the 
percentage of dauers was scored. Δ4-DA and Δ7-DA43,44 were used alternatively in dauer rescue experiments with 
working concentrations that were chosen (1 µM and 90nM, respectively).
To determine dauer formation of daf-9(dh6) strain, embryos were placed on NGM plates with E. coli com-
plemented with Δ7-DA or endocannabinoids. dhEx24 is an extrachromosomal array carrying active DAF-9 and 
nuclear GFP. After 3 days daf-9 null worms were identified on the basis of the absence of GFP signal and dauer 
formation was scored47.
Cholesterol deprivation assay. The protocol from Matyash et al.3 was carried out. Briefly, to produce 
sterol-depleted media, agar was replaced by agarose (Sigma-Aldrich) that was washed three times with chloro-
form to deplete the trace sterols in it. E. coli NA22 was grown in low-glucose, sterol-free DMEM culture medium 
(Sigma-Aldrich). Bacteria were rinsed with M9 before use and concentrated 20 times. Then the plates were seeded 
with 100 µl of bacteria and the supplements were added (or solvent carrier as negative control). 80–100 L1s were 
plated, incubated at 15° C for 6 days, and finally scored for percentage of dauers formed.
Lipid extraction and endocannabinoid analysis by HPLC-MS/MS. The protocol is an adaptation 
from Folch (1957)48. Lipid extracts were generated from approximately 100 mg of frozen worm pellets belonging 
to N2, daf-7, fat-3 and daf-7;fat-3 grown at 20 °C. The pellets were thawed on ice in 1.3 ml methanol and subjected 
to 4 min sonication on ice. After sonication, 1000 ppb of the internal standard 2-AG-d5 were added followed by 
2.6 ml chloroform and 1.3 ml 0.5 M KCl/0.08 M H3PO4 to a final ratio of 1:2:1. Samples were vortexed and then 
sonicated in an ultrasonic water bath for 15 min. After vortexing twice for 1 min, samples were centrifuged for 
10 min at 2.000 g to induce phase separation. The lower phase was collected into a clean glass tube, dried under 
nitrogen and re-suspended in 100 µl of acetonitrile.
2-AG and AEA were quantified from nematode samples by liquid chromatography (Ultimate 3000 RSLC 
Dionex, Thermo Scientic) coupled with an ESI triple quadrupole mass spectrometer (TSQ Quantum Access 
Max (QQQ), Thermo-Scientific). Reversed-phase HPLC column (C18 Hypersil-GOLD (50 x 2.1 mm), Thermo 
Scientific) was carried out employing the following step-wise gradient: 0 min (water 4:6 acetonitrile); 0.5 min 
(water 4:6 acetonitrile); 6.5 (water 2.5:7.5 acetonitrile); 7.5 min (water 2.5:7.5 acetonitrile); 8 min (water 4:6 ace-
tonitrile). Column temperature was maintained at 40 °C and autosampler tray temperature was set at 10 °C. The 
following ionization conditions were used: ESI, positive-ion mode; drying gas (N2) temp., 300 °C; drying gas flow 
rate, 10 l/min; nebulizer pressure, 10 UA, and cap. voltage, 4 kV. Analyte detection was performed using NRM 
with the following transitions: m/z 379,2→289,2 for 2-AG; m/z 348,2→62,2 for AEA and m/z 384,2→289,2 for 
2-AG-d5. Deuterated internal standard 2-AG-d5 was used for quantification, and peak-area ratios of the analyte 
to the internal standard were calculated as a function of the concentration ratios of the analyte to the internal 
standard. Sample concentrations were calculated from the calibration curve using an equally weighted linear 
regression (X) algorithm, where X represents concentration.
Generation of daf-7;fat-3 and daf-7;fat-4 double mutant strains. Homozygous fat-3(ok1126) male 
worms were crossed to daf-7(e1372) hermaphrodites. The hermaphrodites from the progeny laid eggs that at 
25 °C developed into dauers or adults. The dauers were relocated to 15 °C to re-enter reproduction and their 
progeny was screened using PCR for homozygous daf-7(e1372);fat-3(ok1126) individuals. Using an equivalent 
strategy, homozygous fat-4(ok958) male worms were crossed to daf-7(e1372) hermaphrodites. The hermaphro-
dites from the progeny laid eggs that at 25 °C developed into dauers or adults. The dauers were relocated to 15 °C 
to re-enter reproduction and their progeny was screened using PCR for homozygous daf-7(e1372);fat-4(ok958) 
individuals.
GC-MS determination of fatty acid methyl-ester content. Lipid extraction was performed using 
Bligh and Dyer49 method. Briefly, the N2 and fat-3 were grown at 20 °C on E. coli OP50 for 72 h and then har-
vested from plates with 5–10 ml of M9 buffer. For the interference assay with let-767 RNAi, daf-7 worms were 
grown on E. coli OP50 with TH115 empty vector as a control, and with RNAi against let-767 at 20 °C for 72 h. 
Subsequently, worms were harvested as described above. Thereafter, worms were washed three times with M9 
buffer to eliminate excess bacteria. The worm pellet was transferred to a glass tube and 3 ml of a chloroform:meth-
anol 1:2 mixture was added. Dibutylhydroxytoluene (BHT) was added as an antioxidant at a final concentration 
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of 5 µg/ml. The samples were incubated for 12 h at −20 °C. After incubation the samples were centrifuged and the 
supernatants were transferred to a new tube. 1 ml of KCl (1M) and 1 ml of chloroform were added to the samples, 
the samples were mixed by vortexing and then centrifugated for 2 min at 2000 g. Finally, the organic phases were 
transferred to new tubes and dried under N2 flow.
Chemical General Information. 1H and 13C NMR spectra were acquired on a Bruker Avance II 300 MHz 
(75.13 MHz) using CDCl3 as solvent. Electrospray Ionization High-Resolution Mass Spectra (ESI-HRMS) were 
recorded on a Bruker MicrOTOF II with lock spray source. IR spectra were obtained using an FTIR Shimadzu 
spectrometer. Chemical reagents were purchased from commercial suppliers and used without further purifi-
cation, unless otherwise noted. Solvents were analytical grade or were purified by standard procedures prior to 
use. Yields were calculated for material judged homogeneous by thin layer chromatography (TLC) and nuclear 
magnetic resonance (1H-NMR). All reactions were monitored by thin layer chromatography performed on silica 
gel 60 F254 pre-coated aluminum sheets, visualized by a 254 nm UV lamp, and stained with an ethanolic solution 
of 4-anisaldehyde. Column flash chromatography was performed using silica gel 60 (230–400 mesh).
2-AG-d5 preparation. For obtaining 2-AG-d5 as a deuterated internal standard for quantification assays, we 
followed a three-step protocol: differential protection, esterification and deprotection.
Differential protection step: In order to only protect primary alcohols, a solution of glycerol-d8 (38 mg, 0.18 
mmol) in anhydrous dichloromethane (5 ml) under inert atmosphere was prepared and cooled at −78 ºC. Then, 
collidine (54 mg, 0.36 mmol) and tert-butyl dimethyl silyl chloride (TBDMSCl, 70 mg, 0.54 mmol) was added. 
The mixture reacted for 3 h at −78 ºC, then warmed to room temperature and stirred for additional 12 h. Brine 
was added and the solution was extracted with dichloromethane. The combined organic extracts were dried over 
sodium sulfate and evaporated. Products were purified by column chromatography on silica gel with increas-
ing hexane/ethyl acetate gradients. 1-O,3-O-Bis(TBDMS) glycerol-d6 was obtained as a colorless liquid in 44% 
yield (55 mg). For the esterification step, a solution of 1-O,3-O-Bis(TBDMS) glycerol-d6 (10 mg, 0.03 mmol) in 
anhydrous dichloromethane (2 ml) under inert atmosphere was prepared and cooled at 0 ºC. Next, arachidonic 
acid (36 mg, 0.12 mmol), 4-dimethylaminopyridine (15 mg, 0.12 mmol) and N,N’-dicyclohexylcarbodiimide 
(15 mg, 0.12 mmol) were added in that order. The mixture reacted for 3 h at 0 ºC, and was then warmed to 
room temperature and stirred for additional 12 h. Water was added and the solution was extracted with dichlo-
romethane. Combined organic extracts were dried over sodium sulfate and evaporated. Products were puri-
fied by column chromatography on silica gel with increasing hexane/ethyl acetate gradients. 1-O,3-O-bis(TBD
MS)−2-AG-d5 was obtained as a yellowish liquid in 80% yield (15 mg). For the deprotection step, a solution of 
1O,3O-Bis(TBDMS)−2-AG-d5 (15 mg, 0.025 mmol) in tetrahydrofuran (2 ml) was prepared. Then, a 1M solu-
tion of tetrabutylammonium fluoride (150 ml, 0.15 mmol) was added cautiously dropwise. Once the reaction 
was complete (1 h), water was added and the solution was extracted with dichloromethane. Combined organic 
extracts were dried over sodium sulfate and evaporated. A quantitative amount of product 2-AG-d5 (10 mg, quan-
titative) was obtained as a yellowish liquid.
Methyl- ester preparation. For the derivatization of fatty acids prior to GC-MS analysis, 0.5 ml of anhy-
drous sodium methoxide 0.5 M were added to the lipid samples and then incubated 30 min at room temperature. 
Then 1 ml of HCl (2 N) was added for neutralization of the reaction. The fatty acid methyl esters were extracted 
with hexane and finally resuspended in 500 ml of hexane.
For obtaining the AA and C17iso methyl-esters used for supplementation assays we followed a protocol based 
on Walker et al.50. Briefly, a solution of diazomethane in diethyl ether was added cautiously dropwise to a stirred 
solution of the appropriate fatty acid (50 mg, 0.16 mmol) in dichloromethane (5 ml) until the yellow color per-
sisted. The excess of the reagent was vented under a nitrogen purge. The solvent was evaporated and the product 
dried under vacuum to provide the methyl ester as a colorless oil (54 mg, quantitative) that was used without 
further purification.
Gas chromatography coupled to mass spectrometry (GC-MS). The methyl ester analysis was per-
formed in a Shimadzu GC-2010 Plus equipment. The column used was a Supelco WAX-10 (Sigma Aldrich) 100% 
polyethyleneglycol. The helium flux was 1 ml/min and the heating program was 180 °C (0 min to 32 min) and 
then a gradient increasing 3 °C/min from 180 °C to 240 °C. The split was 1/30 and the ionization voltage was 70 
eV with an ionic range from 50 to 600 Da. The ion specters were registered as relative abundance in function of 
mass/charge (m/z). Peak assignation was done using the mixture of standards of fatty acid methyl esters AGs 
Supelco (Sigma Aldrich).
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